PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo targets incurable esophageal cancer
Disease control OngoingThis early-phase study tested a drug called adavosertib combined with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:08 UTC
-
Experimental combo shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy could help control advanced gastroesophageal cancer that cannot be surgically removed. Sixteen participants received the combination to see if it could shrink or elimin…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
Virus-Enhanced treatment shows promise for Hard-to-Treat esophageal cancer
Disease control OngoingThis early-phase trial studies a new treatment for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. It combines a cancer-killing virus (OBP-301) with standard chemotherapy and radiation. The main goal is to check safety and find the best dose, w…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New combo before surgery shows promise against esophageal cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can better control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New combo therapy shows promise in shrinking esophageal tumors before surgery
Disease control OngoingThis study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC